1 B reast cancer is the most prevalent malignancy in women and metastatic breast cancer is a leadi i ing cause of mortality, accounting for more than 400 000 deaths annually worldwide. 1 Even though ani i thracyclines and taxanes are the most active agents in breast cancer, treatment failure occurs in a substantial number of patients and median survival for metastati i ic breast cancer remains 2 to 3 years. 2i4 Resistance to antineoplastic agents, and in particular anthracyclines and taxanes, is a limiting factor in breast cancer therapy, either after metastatic or adjuvant treatment. 3, 5 With increasing use of anthracyclines and taxanes for early breast cancer, fewer effective options are available for patients with metastatic disease. 3, 4 Capecitabine is comi i monly used for the treatment of anthracyclinei and/or
Background and oBjectives:
There is an unmet need for new combination treatments, especially for aggres-sive, visceral, and high tumor burden metastatic breast cancer. Gemcitabine (GEM) has shown synergy with vinorel-bine (VRL) in preclinical models, and has a toxicity profile that is different from VRL, another recently approved cyto-toxic drug that seems to be effective in the treatment of breast cancer. Patients and Methods: We studied the efficacy and side effects of the GEM-VRL combination as first-line che-motherapy in patients in an open-label, single arm, phase II study in patients with locally advanced or metastatic breast cancer who had been previously treated with an anthracycline-based regimen in the adjuvant/neoadjuvant setting. results: Of the 74 patients enrolled, 72 patients were evaluable for the primary treatment outcome (tumor response rates). Four patients (6%) had a complete response and 26 patients (36%) had a partial response. Nineteen patients (26%) had stable disease. The median time to disease progression was 37 weeks (range, 1-60 weeks). Median duration of response was 43 weeks (range, 8.6 to 55 weeks) and one-year survival was 77% (95% confidence interval, 64% to 86%). Grade 3-4 neutropenia without fever was reported in 10% of patients, thrombocytopenia in 1%, and febrile neutropenia in 11%. The most common clinical grade 3-4 toxicities were nausea (24%) and diarrhea and stomatitis (11% each). Hospitalizations for adverse events mainly due to anemia, febrile neutropenia, septic shock and hepatic failure occured in 7%. conclusion: With an overall response rate of 42%, the GEM-VRL combination had promising efficacy and good tolerability in metastatic breast cancer patients. taxaneipretreated metastatic breast cancer; however, objective response rates in phase II studies are only 20% to 28%. 6, 7 Therefore, there is an unmet need for new combination treatments, especially for aggressive, visi i ceral and high tumor burden metastatic breast cancer.
Gemcitabine (GEM) and vinorelbine (VRL) are two of the most recently approved cytotoxic drugs that seem to be effective in the treatment of several solid tumors including breast cancer. Single VRL chemotherapy has been administered as firsti and secondiline treatment in advanced breast cancer. The response rate as firsti line treatment has varied from 35% to 41%. 8, 9 As seci i ondiline treatment, the overall response rate has been reported to be 16%, 27%, and 32%. 8, 10, 11 When given in combination with other drugs, the secondiline response rate was higher. 12, 13 GEM is also active against breast cancer and has demonstrated singleiagent response rates of approximately 20%. 14 A short pilot study of pretreated patients 15 and a doseifinding study, 16 both in patients with metastatic breast cancer, indicated promising results, although myi i elotoxicity was again the dominant side effect. Data on this combination in Egyptian patients is needed to assess it as a possible option for metastatic breast cancer pai i tients pretreated with anthracyclines in this population of patients.
Patients and Methods
In an open label, single arm, nonirandomized, unblinded phase II study in patients with locally advanced or metai i static breast cancer who had been previously treated with one anthracycline with/without taxaneibased regimen in the adjuvant/neoadjuvant or firstiline metastatic setting, we studied the GEMiVRL combination in a 3iweekly schedule as firstiline chemotherapy. The study was coni i ducted in five different oncology centers in Egypt. The primary objective of this study was to assess the efficacy of this combination by determining overall response rate. Secondary endpoints were the assessment of the toxicity of GEM in combination with VRL, as well as the time to disease progression and the survival at one year.
Patients were included in the study only if they met all of the following criteria: histological or cytological diagi i nosis of breast carcinoma with evidence of unresectable, locally recurrent, or metastatic disease, or the presence of metastatic or localiregional recurrent disease, accordi i ing to the American Joint Committee on Cancer. 17 Also required were uniidimensionally measurable lesions with clearly defined margins that were clearly measuri i able by CT, chest xiray or clinical examination, accordi i ing to RECIST criteria; 18 no prior chemotherapy for metastatic or locoiregionally recurrent disease, or prior radiotherapy must have been completed at least 30 days before study entry; no concurrent hormonal therapy for metastatic breast cancer, a Karnofsky performance status of ≥70, an estimated life expectancy of at least 6 months, patient compliance and geographic proximity that ali i lowed for adequate followiup, adequate organ function and signed informed consent from the patient or legal representative. Patients were excluded from the study if there was concurrent administration of other tumor therapy, pregnancy or breastifeeding, serious concomii i tant disorders that would compromise the safety of the patient or compromise the patient' s ability to complete the study, a second primary malignancy that was clinii i cally detectable at the time of consideration for study enrollment, known or suspected brain metastasis, bone metastasis, pleural effusion or ascitis as the only sites of disease.
GEM and VRL were given on days 1 and 8 every 3 weeks. GEM was used at a dose of 1000 mg/m 2 and VRL at 25 mg/m 2 . Every cycle, VRL was administered before GEM. Therapy was continued until there was evidence of progressive disease, the patient experienced unacceptable toxicity, the investigator decided that the patient should be discontinued, the patient requested discontinuation, or the patient received 6 cycles of the regimen. Any adverse event considered at least possibly related to treatment was defined as toxicity.
After baseline evaluation, tumor status was assessed every other treatment cycle (approximately 6 weeks) while on study therapy and every 6 to 8 weeks during postitreatment followiup until documented disease progression, death or 12 months after study enrollment, whichever occured first. Responses were assessed accordi i ing to Response Evaluation Criteria in Solid Tumors, version 1.0, 17 and required confirmation at least 4 weeks after first evidence of response.
Patients having documented disease progression were monitored for survival approximately every 2 months, until death or 12 months after study enrollment, whichi i ever occured first. Patients were assessed for toxicity according to the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 3.0. 19 The Simon twoistage design was used to test the null hypothesis that the response rate was ≤40% versus the alternative hypothesis that the response rate was ≥55%. 20 Setting the typeiI error rate at 0.04 and typeiII error rate at 0.2, 35 patients were to be enrolled in the first stage of the trial. At the end of the first stage, if 15 or fewer responses were observed the trial was to be terminated. Otherwise, the trial was to go to a second stage, enrolli i ing an additional 45 evaluable patients. If at least 40 of a total of 80 evaluable patients responded, the treatment was then considered promising enough to warrant furi i ther development.
The primary endpoint of this study was tumor rei i sponse rate, which was defined as the number of patients with a confirmed response (complete response [CR] or partial response [PR] divided by the number of patients who qualified for tumor response analysis, i.e., the eni i rolled eligible patients with measurable disease and at least one dose of study therapy). These qualified patients were the basis of the duration of response analysis, one of the secondary endpoints. The other secondary end points of this study included time to disease progression and oneiyear survival rate, which were analyzed on the intentitoitreat basis including all enrolled eligible pai i tients. The KaplaniMeier method was used to estimate original research report gemaTabine wiTH vinOrelbine Hematol Oncol Stem Cell Ther 3(1) First Quarter 2010 hemoncstem.edmgr.com the medians for time to disease progression, duration of response as well as the oneiyear survival rate. 21 All pai i tients who received at least one dose of study drug were evaluated for safety.
results
The 74 patients enrolled in this study had a median age of 45 years ( Table 1 ). The majority were postmenopausi i al. Seventyitwo (97%) had a Karnofsky performance stai i tus of 80% and above. Seventyione patients (96%) were metastatic and only three patients had locally advanced disease (4%). All patients had previously received adjui i vant chemotherapy with anthracyclines for breast cani i cer. Thirtyiseven patients (50%) had lung metastasis, 34 (46%) had liver metastasis, and 44 (60%) had metastasis in three or more sites.
The overall response rate was 42% (95% CI, 30% to 54%) (n=30) in 72 evaluable patients, with a complete response in 4 patients (6%) and a partial response of in 26 patients (36%) ( Table 2 ). Stable disease was reported in 19 patients (26%) and progressive disease in 17 pai i tients (24%). Disease progression was not assessable in 6 (8%). The median duration of response was 43 weeks (range 8.6i55 weeks) ( Figure 1 ).The median time to disi i ease progression ( Figure 2 ) was 36.7 weeks (range, 1i60 weeks). The oneiyear survival rate was 77% (95% CI, 64% to 86%).
Toxicity data was available for all patients ( Table 3 ). The most common grade 3i4 toxicities were vomiting (24%) diarrhea (11%) and stomatitis (11%) ( Table 4 ). Serious clinical adverse events included 18 hospitalizai i tions; 5 (7%) due to adverse events, 2 for platelet transfui i sions and 14 for packediRBC transfusions ( Table 5 ). The mean (SD) number of cycles received for both GEM and VRL was 4.4 (1.8) . Dose reductions occurred in 9.5% of cycles for both GEM and VRL. The dose reduction was mainly due to hematological toxicities for both drugs. None of the patients had more than one dose reduction.
discussion
There is a clear requirement for alternative cytotoxic drugs or regimens with antitumour activity to treat pai i tients with metastatic breast cancer who have already received anthracyclines. Few standard combination chei i motherapy treatments currently exist for this patient population, for which only a few drugs have shown activi i ity as single agents. VRL has been tested in phase II trials in patients with previous treatment with anthracyclines with a reported response rate of 25% and a median time to disease progression of 3 months. 22,23 GEM has shown modest activity (response rate 13%) as a single agent in metastatic breast cancer, especially when used as secondi line or thirdiline treatment. 24 However, GEM in combii i nation with paclitaxel has been approved for the firstiline treatment of metastatic breast cancer, after a large multii i center trial reported that the combination was more efi i fective than singleiagent paclitaxel in terms of response rate, time to disease progression, and overall survival. 25 Because of the activity of VRL and GEM as single agents in pretreated metastatic breast cancer, and the lack of overlapping nonihematological toxic effects, phase II studies were initiated to test the activity of the combination of these two drugs, where the response rates ranged from 36% to 80% with an average of 60%. 26i 40 There was also one phase III trial of the combinai i tion of GEMiVRL versus VRL alone, which reported a response rate for the combination of 36% versus 25 % for VRL alone. In this trial the median progressionifree survival for the combination was 6.3 months versus 4.1 months for VRL alone (P=.001). The main grade 3i4 toxicities reported in this phase III trial were neutroi i penia (65%), febrile neutropenia (10%) and thromboi i cytopenia (11%). 41 The main reported toxicities in the various trials reported in the literature were grade 3i4 neutropenia ranging from 12% 38 to 42%, 31 grade 3i4 anemia ranging from 1%33 to 17% 25 and thrombocyi i topenia grade 3i4 ranging from 1% 32 to 18%. 30 Other frequently reported clinical toxicities were nausea, diari i rhea and asthenia. 26i40 The response rates and disease progression in our study are consistent with the results of previously reported in phase II and III studies.The median duration of response and median time to disi i ease progression are similar to the reported phase III trial where the progression free survival was 6.3 months in the combination arm versus 4.1 months in the single agent VRL arm. 41 Other phase II studies reported time to disease progression between 3 and 6.8 months.
The toxic effects of the combination were managei i able and consisted mainly of grade 3i4 febrile neutroi i penia and clinical toxicities of nausea, diarrhea and stomatitis. The most commonly reported toxicities in previously reported trials were neutropenia, febrile neutropenia, neausia and phlebitis. 26i40 With an overi i all response rate of 42%, the GEMiVRL combination demonstrated promising efficacy and good tolerability in metastatic breast cancer patients. 
